AdrenocorticAl adenocarcinoma is a rare malignancy with an incidence of approximately 1-2 per million population [1, 2] . Although clinical evidence of steroid excess occurs in approximately 60% of cases [1] , feminizing symptoms secondary to estrogen-secretion are extremely uncommon [3, 4] Abstract. Estrogen-secreting adrenal cancers are extremely rare, with feminizing symptoms attributed to aromatase expression in the adrenal tumor. We describe a case of hypogonadotropic hypogonadism as a consequence of aberrant aromatase expression in a patient with adrenocortical adenocarcinoma. A 54 year-old man presented with a two month history of gynecomastia and reduced libido. Endocrine biochemistry at presentation showed hypogonadotropic hypogonadism (LH 2.4 U/L, FSH <1.0 IU/L, testosterone 2.8 nmol/L) with increased serum estrone (E1, 821 pmol/L) and estradiol (E2, 797 pmol/L) and subclinical ACTH-independent hypercortisolism (serum cortisol post 1mg overnight dexamethasone suppression test, 291 nmol/L). A right adrenal mass was identified on CT scanning and the patient underwent an open adrenalectomy. Post-operative evaluation showed normalization of serum levels of E1 (95 pmol/L), E2 (109 pmol/L), testosterone (11.4 nmol/L), LH (4.1 U/L) and FSH (5.9 IU/L), and of cortisol dynamics. Immunohistochemistry of the adrenal cancer confirmed aberrant expression of aromatase in most, although not all, carcinoma cells. Transcripts associated with utilization of promoters II, I.1 and I.3 were prominently represented in the tumor aromatase mRNA. This case highlights that clinical features of feminizing adrenocortical carcinomas can be secondary to estrogen production by aberrantly transcribed and translated aromatase within the tumor. Even in males, gonadotropin secretion is subject to predominantly estrogen-mediated feedback-inhibition. The diagnosis of adrenocortical adenocarcinoma should be considered in men presenting with low testosterone and gonadotropins, particularly in the presence of feminizing features.
cytochrome P450 aromatase (aromatase) is the final and rate-limiting step in estrogen biosynthesis and is the product of the CYP19 gene. The enzyme catalyses the conversion of C19 steroids, androstenedione, testosterone and 16α-hydroxyandrostenedione, to estrone (E 1 ), estradiol (E 2 ) and estriol respectively in a tissuedependent manner, according to substrate availability. In adult humans, aromatase is expressed in ovaries, placenta and adipose tissue with low levels in testes and brain [5] . In the past, feminizing symptoms of adrenocortical carcinomas had been attributed to peripheral aromatization of adrenal androgens [6] . However, 246 and 220 (reference range, 0-1000), metadrenaline (pmol/L) 167 and 155 (reference range, 0-600)].
The patient underwent open adrenalectomy and an enlarged and encapsulated 145g (70x70x65mm) right adrenal gland was removed without complication. Intra-operatively, there was no evidence of metastatic disease. Histological examination revealed that the gland was mostly occupied by a nodule composed of predominantly eosinophilic cells with diffuse architecture, focal confluent necrosis, moderate nuclear pleomorphism, abnormal mitoses, a raised mitotic count (at least 11 per 50 high power fields) and broad fibrous bands (Fig. 1A-C) . The Weiss score was therefore 6 out of 9, thereby securing the diagnosis of adrenal cortical carcinoma [8, 9] . The Ki-67 index was 44.1%. There was no capsular, sinusoidal or vascular invasion. The findings were those of an adrenal cortical adenocarcinoma (pT2 NX MX) [10, 11] . Immunohistochemistry with a mouse monoclonal antibody against human aromatase (Novartis clone #677) [12] showed most, although not all, carcinoma cells to stain positively. Within the positively staining carcinoma cells, the labeling was diffuse or finely granular within the cytoplasm (Fig. 1D ). Of particular note were densely staining cytoplasmic aggregates or "inclusions" of various sizes and shapes observed within many of the positive carcinoma cells (Fig. 1D and E) . Aromatase recent case reports have demonstrated local aromatase mRNA and activity in the tumorous adrenal tissue [7] .
We present the case of a man with a short history of gynecomastia and loss of libido secondary to an estrogen-producing adrenocortical carcinoma. Immunostaining of the adrenal tumor revealed the presence of aromatase protein in cytoplasmic aggregates suggesting abnormal production and processing of the enzyme.
case report
A 54 year-old man presented with a 2 month history of bilateral gynecomastia and reduced libido. There was no history of exposure to exogenous estrogens, androgen antagonists or of excess alcohol consumption. Physical examination revealed symmetrical 4cm x 4cm gynecomastia and diminished testicular volume (15 and 12 mL). He was found to have profound biochemical hypogonadotropic hypogonadism, associated with markedly elevated estrogen levels and abnormal cortisol dynamics (Table 1) . Contrast-enhanced computerized tomographic scanning identified an approximately 6-6.5cm relatively homogenous enhancing right adrenal mass which demonstrated areas of necrosis on magnetic resonance imaging. Plasma metanephrines were normal [normetadrenaline (pmol/L) teristic of that of an estrogen-secreting tumor with increased circulatory levels of E 1 and E 2 , low serum testosterone and gonadotropins and a moderately elevated serum 11-deoxycortisol. Suppressed gonadotropin secretion is a recognized consequence of aromatization of testosterone to E 2 [16] , demonstrating that even in men gonadotropin secretion is predominantly under estrogen-mediated feedback inhibition. Increased serum 11-deoxycortisol suggests impaired 11β-hydroxylase activity within the tumor. Although decreased 11β-hydroxylase activity is a characteristic feature of feminizing adrenocortical adenocarcinomas [4, 15, 17] , it is unclear whether this is a consequence of estrogen excess or a direct effect of the neoplastic process. Even though the patient was normotensive without Cushingoid features, the abnormal cortisol dynamics illustrate the importance of actively seeking evidence for autonomous cortisol secretion in all patients presenting with feminizing adrenocortical carcinomas. Patients with tumorous adrenal cortisol hypersecretion can develop cardiovascular collapse post-adrenalectomy, due to "suppression" of the contralateral normal adrenal gland, unless peri-and post-operative glucocorticoids are administered. In the setting of a low serum testosterone, the absence of supranormal levels of LH and FSH was suggestive of hypogonadotropic hypogonadism, although unequivocal diagnosis would have required a GnRH stimulation test.
Aromatase mRNA has been previously demonstrated in feminizing adrenal tumors [7, 17] . However, the presence of biologically active translated protein has typically been assumed, based on the detection of aroimmunoreactivity was not observed in stromal cells of the adrenal gland. The aromatase transcripts associated with utilization of the gonadal-associated aromatase promoter II were prominently represented in the tumor aromatase mRNA. However, significant amounts of transcripts associated with both promoters I.1 and I.3 were observed, while there was no evidence for promoter I.4-associated activity (Fig. 1G) .
Urine steroid profiles pre-operatively showed an increase in 5β-relative to 5α-reduced metabolites and of pregnanediol, pregnenetriol and a number of unusual additional metabolites suggestive of steroid production by the adrenal mass (Table 2) . Post-operatively, the relative excesses previously noted were no longer present and the ratio of 5β-to 5α-reduced steroids was reversed with relatively higher levels of 5α-reduced steroids, consistent with the increased levels normally found in adult males compared to females [13] .
Post-operatively, gynecomastia regressed and libido improved, accompanied by normalization of all biochemical parameters (Table 1) . Three years later there is no clinical, radiological or endocrine evidence of recurrent disease.
discussion
Estrogen-secreting adrenal tumors are an uncommon cause of gynecomastia and are almost invariably malignant [14] . Feminizing symptoms are attributed to the in situ generation of E 1 through aberrant aromatisation of adrenal androgens with trivial or no estrogen secretion occurring in normal adrenals [15] . Our patient's pre-operative endocrine profile was charac- from peripheral E 1 conversion via 17β-hydroxysteroid dehydrogenase type 1 (17HSD1) [7, 17] . However, we recently showed that adrenal cancer cells express the reductive type 5 17β-hydroxysteroid dehydrogenase (AKR1C3) which is capable of converting E 1 to E 2 as well as androstenedione to testosterone, indicating the capacity for direct E 2 production by the tumor [12] . Locally synthesized estrogens may promote cellular proliferation in aromatase expressing female breast carcinomas [20, 21] . Although we did not measure receptor activity, estrogen receptor β expression has previously been reported in a steroid-producing adrenocortical cell line [22] . Accordingly, it is possible that estrogens produced by the adrenal carcinoma cells may have contributed to the high rate of cellular proliferation observed in our patient. In summary, although estrogen-secreting adrenocortical carcinomas are extremely rare, there are now sufficient data to indicate how aberrant aromatase expression can result in a characteristic clinical and biochemical presentation. The diagnosis should be considered in all patients presenting with hypogonadotropic hypogonadism, particularly if there is also gynecomastia. matase activity by the tritiated water technique, even though aromatase activity in adrenocortical adenocarcinoma is approximately 50-fold lower than that found in human placenta [4, 17] . In the present report, we demonstrated the distribution of the translated aromatase protein within an adrenal tumor, the feminizing features and endocrinological presentation of the patient serving as an indicator that the immunoreactive aromatase was biologically functional. Under normal conditions, aromatase is located in the endoplasmic reticulum of estrogen producing cells [18] . In our patient, cellular immunostaining was heterogeneous. In positive cells, immunostaining was diffuse or finely granular within the cytoplasm, with additional immunopositive inclusions or aggregates.
The site-specific expression of aromatase is regulated by tissue-specific promoters: proximal promoter II in ovary, distal promoter I.1 in placenta and promoters I.3 and I.4 in adipose tissue [5] . Promoter II is proximal to the translation start site and is considered to be the primitive promoter regulating estrogen expression. As has been shown in adrenocortical tumors [19] , and others, promoter II was prominent for the pathological aromatase expression in our patient. However, transcripts derived from promoters I.1 and I.3 were also detectable. While promoter I.3 transcripts have been previously reported in adrenal tumors, to our knowledge this is the first report of adrenal tumor aromatase expression utilizing the so-called 'placental' promoter, which occurred in the absence of placental tissue within the tumor.
Although serum estrogens were elevated, the E 1 :E 2 ratio was approximately one. In the context of low pre-operative peripheral testosterone levels, it has previously been suggested that E 2 production originates references
